InsiderTrades

Form 4 for CADL Candel Therapeutics, Inc.

Accepted 2021-08-02 00:00:00 ET · period of report 2021-07-29 · accession 0000899243-21-031104 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DI 2021-08-02 2021-07-29 CADL Martell Christopher Dir C - Cnv Deriv — +283.5K 283.5K New —
DI 2021-08-02 2021-07-29 CADL Martell Christopher Dir P - Purchase $8.00 +125.0K 125.0K New +$1.00M
DI 2021-08-02 2021-07-29 CADL Martell Christopher Dir C - Cnv Deriv $0.00 -696.9K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-07-29 C A 283,514 — 283,514 I By GTAM1 2012 ADV LLC — — (F1) These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date. (F2) Shares held by GTAM1 2012 ADV LLC, for which the Reporting Person serves as manager. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.
2 Common Common Stock 2021-07-29 P A 125,000 $8.00 125,000 I By GTAM1 2012 LLC — — (F3) Shares held by GTAM1 2012 LLC, which is wholly owned by a trust for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.
3 Derivative Series B Preferred Stock 2021-07-29 C D 696,851 $0.00 0 I By GTAM1 2012 ADV LLC — · — to — 283,514 Common Stock (F2) Shares held by GTAM1 2012 ADV LLC, for which the Reporting Person serves as manager. The Reporting Person disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any. (F1) These shares of Series B Preferred Stock were convertible at any time at the holder's election and automatically converted on a one-for-2.4579 basis into shares of the Issuer's common stock immediately upon the closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series B Preferred Stock had no expiration date.